2019
DOI: 10.1016/j.phymed.2019.09.130
|View full text |Cite
|
Sign up to set email alerts
|

First prospective study of a combined immune therapy of checkpoint inhibitors ± CTX plus Viscum album L. in non-small cell lung cancer (NSCLC) in UICC stage III B-IV B

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 3 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?